[go: up one dir, main page]

HK1208499A1 - Dual receptor antagonistic antigen-binding proteins and uses thereof - Google Patents

Dual receptor antagonistic antigen-binding proteins and uses thereof Download PDF

Info

Publication number
HK1208499A1
HK1208499A1 HK15108981.7A HK15108981A HK1208499A1 HK 1208499 A1 HK1208499 A1 HK 1208499A1 HK 15108981 A HK15108981 A HK 15108981A HK 1208499 A1 HK1208499 A1 HK 1208499A1
Authority
HK
Hong Kong
Prior art keywords
dual receptor
binding proteins
receptor antagonistic
antagonistic antigen
antibodies
Prior art date
Application number
HK15108981.7A
Other languages
English (en)
Chinese (zh)
Inventor
Han Huiquan
Zhou Xiaolan
Chen Qing
Tsai Mei-Mei
Original Assignee
Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen, Inc. filed Critical Amgen, Inc.
Publication of HK1208499A1 publication Critical patent/HK1208499A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15108981.7A 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof HK1208499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261658237P 2012-06-11 2012-06-11
US61/658,237 2012-06-11
PCT/US2013/045245 WO2013188448A2 (fr) 2012-06-11 2013-06-11 Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations

Publications (1)

Publication Number Publication Date
HK1208499A1 true HK1208499A1 (en) 2016-03-04

Family

ID=49758865

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108981.7A HK1208499A1 (en) 2012-06-11 2013-06-11 Dual receptor antagonistic antigen-binding proteins and uses thereof

Country Status (21)

Country Link
US (5) US9453080B2 (fr)
EP (3) EP3540070A1 (fr)
JP (1) JP2015525230A (fr)
KR (1) KR20150030706A (fr)
CN (1) CN104540961A (fr)
AU (1) AU2013274347B2 (fr)
BR (1) BR112014031028A2 (fr)
CA (1) CA2877669A1 (fr)
CL (1) CL2014003372A1 (fr)
CO (1) CO7240399A2 (fr)
EA (1) EA201492282A1 (fr)
HK (1) HK1208499A1 (fr)
IL (1) IL236133A0 (fr)
MA (1) MA37761A1 (fr)
MX (1) MX2014015195A (fr)
NZ (1) NZ703724A (fr)
PE (1) PE20150642A1 (fr)
PH (1) PH12014502754A1 (fr)
SG (2) SG10201610356YA (fr)
TN (2) TN2015000448A1 (fr)
WO (1) WO2013188448A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013188448A2 (fr) * 2012-06-11 2013-12-19 Amgen Inc. Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
PT3835310T (pt) 2012-09-13 2024-05-20 Bristol Myers Squibb Co Proteínas de domínio de estrutura à base de fibronectina que ligam à miostatina
CA2969800A1 (fr) * 2014-12-08 2016-06-16 Novartis Ag Antagonistes de la myostatine ou de l'activine utilisables en vue du traitement de la sarcopenie
GB201500464D0 (en) * 2015-01-12 2015-02-25 Crescendo Biolog Ltd Method of producing optimised therapeutic molecules
CA3014197A1 (fr) * 2016-02-22 2017-08-31 Ravindra Kumar Antagonistes d'actrii pour leur utilisation dans l'accroissement de l'activite immunitaire
SI3426680T1 (sl) * 2016-03-10 2025-07-31 Acceleron Pharma Inc. Vezavni proteini receptorja aktivina tipa 2 in njihove uporabe
JP7139326B2 (ja) 2016-11-10 2022-09-20 ケロス セラピューティクス インコーポレイテッド アクチビンＩＩａ型受容体変異体および同変異体を含む医薬組成物
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018162931A1 (fr) * 2017-03-10 2018-09-13 Ucl Business Plc Procédé concernant l'inhibition de la voie de la myostatine
WO2018183376A1 (fr) * 2017-03-28 2018-10-04 Rigel Pharmaceuticals, Inc. Anticorps spécifique d'acvr2a et son procédé d'utilisation
KR20250059538A (ko) 2017-11-09 2025-05-02 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CN112292144B (zh) 2018-01-12 2025-03-21 科乐斯疗法公司 激活素受体iib型变体及其使用方法
CA3098679A1 (fr) 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Variants du recepteur de l'activine de type iia et leurs procedes d'utilisation
AU2020284038A1 (en) * 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
KR20230004515A (ko) 2020-03-20 2023-01-06 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법
WO2021189006A1 (fr) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Procédés d'utilisation de variants du récepteur de l'activine de type iia
WO2021189010A1 (fr) * 2020-03-20 2021-09-23 Keros Therapeutics, Inc. Procédés d'utilisation de variants de récepteur de l'activine de type iib
EP4279594A4 (fr) * 2021-01-13 2024-11-27 Astellas Pharma Inc. Liaison d'anticorps multispécifiques à actriia, actriib et fn14
WO2025027052A1 (fr) 2023-07-31 2025-02-06 Sixpeaks Bio Ag Conjugués d'anticorps et protéines de fusion

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0739904A1 (fr) 1989-06-29 1996-10-30 Medarex, Inc. Réactifs bispécifiques pour le traitement du SIDA
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992000373A1 (fr) 1990-06-29 1992-01-09 Biosource Genetics Corporation Production de melanines a l'aide de microorganismes transformes
FR2664073A1 (fr) 1990-06-29 1992-01-03 Thomson Csf Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1993012227A1 (fr) 1991-12-17 1993-06-24 Genpharm International, Inc. Animaux transgeniques non humains capables de produire des anticorps heterologues
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
CA2102511A1 (fr) 1991-05-14 1992-11-15 Paul J. Higgins Anticorps heteroconjugues pour le traitement de l'infection a vih
WO1992022670A1 (fr) 1991-06-12 1992-12-23 Genpharm International, Inc. Detection precoce d'embryons transgeniques
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
WO1993008829A1 (fr) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions induisant la destruction de cellules infectees par l'hiv
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP0648265A4 (fr) 1992-06-18 1996-12-04 Genpharm Int Procede de production d'animaux transgeniques non-humains abritant un chromosome artificiel de levure.
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
CA2161351C (fr) 1993-04-26 2010-12-21 Nils Lonberg Animaux transgeniques, pouvant produire des anticorps heterologues
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
CA2574777C (fr) 2004-07-23 2015-09-01 Acceleron Pharma Inc. Polypeptides du recepteur actrii, procedes et compositions correspondants
EP2052088A2 (fr) 2006-08-02 2009-04-29 Genizon Biosciences Carte génique des gènes humains associés au psoriaris
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
WO2010062383A2 (fr) 2008-11-26 2010-06-03 Amgen Inc. Polypeptides de récepteur stabilisés et leurs utilisations
NO2424895T3 (fr) * 2009-04-27 2018-02-03
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
EP2793925B1 (fr) 2011-12-19 2019-03-20 Amgen Inc. Variants polypeptidiques du récepteur de l'activine, seuls ou en combinaison avec une chimiothérapie, et leurs utilisations
WO2013188448A2 (fr) * 2012-06-11 2013-12-19 Amgen Inc. Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
JP6071725B2 (ja) 2013-04-23 2017-02-01 カルソニックカンセイ株式会社 電気自動車の駆動力制御装置

Also Published As

Publication number Publication date
AU2013274347B2 (en) 2018-03-08
US10266598B2 (en) 2019-04-23
AU2013274347A1 (en) 2015-02-05
PH12014502754A1 (en) 2015-03-02
EP2859114A2 (fr) 2015-04-15
MA37761A1 (fr) 2017-09-29
WO2013188448A3 (fr) 2014-04-10
US20210340262A1 (en) 2021-11-04
WO2013188448A2 (fr) 2013-12-19
EA201492282A1 (ru) 2015-07-30
BR112014031028A2 (pt) 2017-08-15
US20150152194A1 (en) 2015-06-04
JP2015525230A (ja) 2015-09-03
NZ703724A (en) 2017-06-30
SG10201610356YA (en) 2017-01-27
CO7240399A2 (es) 2015-04-17
SG11201408228QA (en) 2015-01-29
WO2013188448A8 (fr) 2014-05-08
US20190256605A1 (en) 2019-08-22
KR20150030706A (ko) 2015-03-20
PE20150642A1 (es) 2015-05-26
TN2014000513A1 (en) 2016-03-30
IL236133A0 (en) 2015-01-29
EP3498857A1 (fr) 2019-06-19
US20170107288A1 (en) 2017-04-20
US20240327526A1 (en) 2024-10-03
US9453080B2 (en) 2016-09-27
CN104540961A (zh) 2015-04-22
EP2859114A4 (fr) 2016-08-03
EP2859114B1 (fr) 2019-05-15
EP3540070A1 (fr) 2019-09-18
US10981999B2 (en) 2021-04-20
CL2014003372A1 (es) 2015-04-10
CA2877669A1 (fr) 2013-12-19
TN2015000448A1 (en) 2017-04-06
MX2014015195A (es) 2015-02-17

Similar Documents

Publication Publication Date Title
HK1208499A1 (en) Dual receptor antagonistic antigen-binding proteins and uses thereof
WO2014152006A3 (fr) Anticorps antihepcidine et leurs utilisations
MX2020013062A (es) Anticuerpos anti proteina relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticoides (gitr) y sus metodos de uso.
WO2016094566A3 (fr) Anticorps dirigés contre les récepteurs de la barrière hématoencéphalique et procédés d'utilisation associés
HK1250513A1 (zh) 抗ox40抗体及其使用方法
WO2014189973A3 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
WO2012064836A9 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
WO2014194274A3 (fr) Protéines de liaison à l'antigène du récepteur de l'oncostatine m
UA123202C2 (uk) Антитіло до тау-білка і його застосування
EP3718531A4 (fr) Préparation liquide d'anticorps humanisé pour le traitement d'une maladie liée à l'il-6
WO2013090635A3 (fr) Composition et méthode pour le diagnostic et le traitement de troubles liés au fer
WO2015009740A3 (fr) Agents de liaison anti-mucine 1 et leurs utilisations
WO2014062659A3 (fr) Méthodes de traitement de maladies oculaires
WO2010086828A3 (fr) Anticorps monoclonaux agonistes anti-trkb
WO2013122544A3 (fr) Anticorps monoclonaux humains neutralisant il-1β
WO2012136534A3 (fr) Utilisation d'un agent sélectionné parmi des anticorps et/ou des antagonistes du facteur de croissance analogue à l'insuline
EP3212666A4 (fr) Anticorps monoclonal humain spécifique de la protéine f du virus respiratoire syncytial (vrs)
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
WO2012166659A3 (fr) Anticorps anti-emr1
HK40061757A (en) Clec12axcd3 bispecific antibodies and methods for the treatment of disease
CR20150030A (es) Proteínas fijadoras de antígeno antagonistas del receptor de acción dual y sus usos
HK40008040A (en) Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins
HK1232467A1 (en) Anti-gitr antibodies and methods of use thereof
HK1241393A1 (en) Humanized anti-hepcidin antibodies and uses thereof